PDS Biotechnology
North Brunswick
About PDS Biotechnology
PDS Biotechnology is a biopharmaceutical company. It develops immunotherapies for cancer and other infectious diseases. It develops products to prevent and treat cervical, ovarian, melanoma, leukemia, pancreatic, oral, multiple myeloma, anal, vulvar, and penile cancers. The company offers PDS0101, a treatment for HPV-related cancers; PDS0102, a pandemic influenza vaccine; and PDS0103, a line of immunotherapy products for non-viral cancers. PDS Biotechnology Corporation was founded in 2005 and is headquartered in North Brunswick, New Jersey.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $73.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2025)
- Ticker: nasdaq:PDSB
- Website: pdsbiotech.com
- Phone: +1 800-208-3343
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/pds-biotechnology-43790 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.